Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE39.5000
- TODAY'S CHANGE (%)-0.8400 (-2.0823%)
- Bid / Lots39.4800/ 2
- Ask / Lots39.5300/ 2
- Open / Previous Close40.0800 / 40.3400
- Day Range
- 52 Week Range
- Volume108,716
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 1120 | 40.35 |
| 09:50 ET | 100 | 40.37 |
| 09:52 ET | 416 | 40.33 |
| 09:56 ET | 100 | 40.56 |
| 09:59 ET | 1262 | 40.4214 |
| 10:06 ET | 152 | 40.47 |
| 10:10 ET | 800 | 40.435 |
| 10:15 ET | 200 | 40.43 |
| 10:17 ET | 608 | 40.265 |
| 10:24 ET | 148 | 40.2388 |
| 10:26 ET | 1340 | 40.19 |
| 10:28 ET | 665 | 40.06 |
| 10:32 ET | 199 | 40.147 |
| 10:35 ET | 100 | 40.01 |
| 10:39 ET | 215 | 40.075 |
| 10:44 ET | 1416 | 40.11 |
| 10:46 ET | 100 | 40.04 |
| 10:48 ET | 3826 | 39.98 |
| 10:50 ET | 600 | 40 |
| 10:53 ET | 300 | 39.985 |
| 10:55 ET | 427 | 39.965 |
| 10:57 ET | 100 | 39.94 |
| 11:00 ET | 200 | 39.95 |
| 11:02 ET | 118 | 39.968 |
| 11:04 ET | 300 | 39.96 |
| 11:06 ET | 500 | 39.91 |
| 11:22 ET | 175 | 39.9102 |
| 11:24 ET | 600 | 39.92 |
| 11:26 ET | 520 | 39.91 |
| 11:27 ET | 1200 | 39.9968 |
| 11:31 ET | 600 | 39.91 |
| 11:36 ET | 1910 | 39.94 |
| 11:42 ET | 300 | 39.955 |
| 11:44 ET | 300 | 39.945 |
| 11:45 ET | 100 | 39.945 |
| 11:47 ET | 100 | 39.89 |
| 11:49 ET | 523 | 39.9599 |
| 11:54 ET | 500 | 39.89 |
| 11:58 ET | 100 | 39.985 |
| 12:00 ET | 100 | 39.9511 |
| 12:02 ET | 100 | 39.99 |
| 12:03 ET | 900 | 39.98 |
| 12:05 ET | 625 | 39.98 |
| 12:09 ET | 1660 | 40.065 |
| 12:12 ET | 3200 | 40.11 |
| 12:14 ET | 100 | 40.11 |
| 12:16 ET | 602 | 40.114 |
| 12:18 ET | 1688 | 40.03 |
| 12:23 ET | 3150 | 40.105 |
| 12:25 ET | 100 | 40.07 |
| 12:34 ET | 300 | 40.07 |
| 12:36 ET | 700 | 40.05 |
| 12:38 ET | 228 | 40.095 |
| 12:39 ET | 272 | 40.1 |
| 12:43 ET | 1149 | 40.04 |
| 12:45 ET | 100 | 40.04 |
| 12:54 ET | 2018 | 40 |
| 12:56 ET | 953 | 40.02 |
| 12:57 ET | 695 | 40.005 |
| 01:03 ET | 200 | 40.04 |
| 01:06 ET | 100 | 40 |
| 01:10 ET | 200 | 40.01 |
| 01:12 ET | 200 | 40.02 |
| 01:14 ET | 100 | 40 |
| 01:15 ET | 400 | 39.99 |
| 01:17 ET | 168 | 40 |
| 01:19 ET | 670 | 39.955 |
| 01:21 ET | 100 | 39.92 |
| 01:28 ET | 533 | 39.86 |
| 01:30 ET | 100 | 39.8 |
| 01:33 ET | 300 | 39.78 |
| 01:35 ET | 300 | 39.75 |
| 01:37 ET | 1500 | 39.82 |
| 01:39 ET | 100 | 39.805 |
| 01:42 ET | 300 | 39.83 |
| 01:44 ET | 216 | 39.79 |
| 01:46 ET | 200 | 39.885 |
| 01:48 ET | 100 | 39.835 |
| 01:50 ET | 300 | 39.835 |
| 01:51 ET | 500 | 39.9 |
| 01:53 ET | 100 | 39.88 |
| 01:55 ET | 500 | 39.86 |
| 02:02 ET | 576 | 39.87 |
| 02:04 ET | 100 | 39.83 |
| 02:06 ET | 100 | 39.8 |
| 02:08 ET | 500 | 39.78 |
| 02:11 ET | 100 | 39.73 |
| 02:18 ET | 1224 | 39.7 |
| 02:22 ET | 300 | 39.68 |
| 02:24 ET | 400 | 39.6 |
| 02:26 ET | 400 | 39.64 |
| 02:27 ET | 300 | 39.67 |
| 02:31 ET | 300 | 39.81 |
| 02:33 ET | 549 | 39.73 |
| 02:38 ET | 300 | 39.67 |
| 02:40 ET | 200 | 39.6975 |
| 02:42 ET | 200 | 39.72 |
| 02:45 ET | 100 | 39.69 |
| 02:47 ET | 300 | 39.69 |
| 02:49 ET | 500 | 39.65 |
| 02:51 ET | 100 | 39.66 |
| 02:54 ET | 645 | 39.66 |
| 02:56 ET | 100 | 39.665 |
| 03:02 ET | 600 | 39.63 |
| 03:03 ET | 100 | 39.6 |
| 03:05 ET | 600 | 39.645 |
| 03:12 ET | 1416 | 39.71 |
| 03:14 ET | 200 | 39.68 |
| 03:16 ET | 597 | 39.52 |
| 03:18 ET | 2355 | 39.5 |
| 03:20 ET | 100 | 39.49 |
| 03:21 ET | 1713 | 39.545 |
| 03:23 ET | 808 | 39.61 |
| 03:27 ET | 1206 | 39.59 |
| 03:30 ET | 385 | 39.55 |
| 03:32 ET | 500 | 39.54 |
| 03:34 ET | 600 | 39.5 |
May 10, 2024
DJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 6:12PM ET on Friday May 10, 2024 by Dow Jones
6:12PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Citigroup, from 5:48PM ET on Friday May 10, 2024 by Dow Jones
5:48PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones*DJ Xenon Pharmaceuticals 1Q Loss/Shr 62c >XENE, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 3.0B | -14.6x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Apogee Therapeutics Inc | 3.1B | -29.1x | --- |
Summit Therapeutics Inc | 3.2B | -2.9x | --- |
Iovance Biotherapeutics Inc | 2.9B | -5.6x | --- |
IDEAYA Biosciences Inc | 3.1B | -20.2x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -14.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
